-
1 day ago | 
medicaldevice-network.com | Ross Law
As reports of an acquisition by one of the leading players in the medical device space percolate, HistoSonics has completed enrolment in a pivotal trial to evaluate its histotripsy platform in treating kidney tumours. The US company’s prospective, multi-centre, single-arm pivotal #HOPE4KIDNEY (NCT05820087) trial is designed to evaluate the effectiveness and safety of the Edison system for the destruction of kidney tissue by treating primary solid renal tumours.
-
2 days ago | 
medicaldevice-network.com | Ross Law
French artificial intelligence (AI)-based medical imaging company Avicenna.ai has secured CE marks for a pair of radiologic screening tools to detect fractures from CT scans. CINA-VCF Quantix is an AI algorithm is used to detect unsuspected vertebral compression fractures (VCFs) in patients undergoing CT scans for unrelated conditions, while CINA-CSpine is designed for the detection and triage of cervical spine fractures.
-
2 days ago | 
medicaldevice-network.com | Ross Law
British healthtech company Huma Therapeutics has initiated the global launch of Hi Scribe, a generative AI (genAI) clinical documentation tool designed to automate and streamline the creation of clinical notes.
-
2 days ago | 
medicaldevice-network.com | Ross Law
The field of Intravascular lithotripsy (IVL), a medical procedure that uses ultrasound shockwaves to break down calcified plaque in arteries, particularly those in the coronary arteries or peripheral arteries, is generating increasing levels of interest. This month’s cover feature looks at the clinical promise IVL holds beyond the financial buzz it has generated in recent times.
-
3 days ago | 
medicaldevice-network.com | Ross Law
RadNet, a DeepHealth company, has acquired See-Mode, an artificial intelligence (AI)-based ultrasound imaging developer. The US company’s acquisition, the terms of which have not been publicly disclosed, will provide it with ultrasound provisions for the detection of thyroid cancer. See-Mode’s AI software uses single or multinodular thyroid ultrasound images to detect nodules and produce standardised reports.
-
3 days ago | 
medicaldevice-network.com | Ross Law
Brain-computer interface (BCI) technology developer Cognixion, and eye-tracking platform specialist Pupil Lab, have forged a strategic partnership to unify their respective technology provisions in an effort to advance research capabilities centred on neurological disease. According to the companies, the partnership addresses a “significant need” that exists in the research community for tools that can simultaneously track visual attention and neural activity.
-
4 days ago | 
medicaldevice-network.com | Ross Law
Reports have emerged that the European Union (EU) has voted to ban Chinese companies from participating in public procurement tenders in the bloc’s medical device sector for contracts valued over €5m ($5.72m) after an EU investigation found that fair access to foreign companies for public tenders in China were not reciprocated.
-
4 days ago | 
pharmaceutical-technology.com | Ross Law
As part of GlobalData's extensive network of websites, this site is dedicated to protecting your privacy. We may store and access personal data such as cookies, device identifiers or other similar technologies on your device and process such data to enhance site navigation, personalize ads and content when you visit our sites, measure ad and content performance, gain audience insights, analyze our site traffic as well as develop and improve our products and services.
-
4 days ago | 
medicaldevice-network.com | Ross Law
Zest has unveiled a new app-based cognitive test designed to screen for the early signs of dementia, as efforts ramp up in healthcare to protect against age-related neurological decline. Developed alongside a team at the University of Cambridge University’s Memory Lab, the London-headquartered biotech’s Precision Memory Assessment (PREMAZ) test is intended to detect subtle cognitive changes that may occur decades before the symptoms of dementia arise.
-
5 days ago | 
medicaldevice-network.com | Ross Law
With early detection of prostate cancer recognised as a critical part in reducing the disease’s mortality rate, PanGIA Biotech has shared results from a study validating its artificial intelligence (AI)-based liquid biopsy in vitro diagnostic (IVD) for detecting early prostate cancer from urine samples.
